Breathtec Biomedical Inc. (BTHCF) 0.2000 $BTHCF
Post# of 273254
Posted On: 09/21/2016 11:17:19 PM
Breathtec Biomedical Inc. (BTHCF) 0.2000 $BTHCF
Breathtec BioMedical to Present at 2016 International Association of Breath Research
Marketwire Canada - Thu Sep 08, 7:30AM CDT
Company Provides Sponsorship Support and Delivers Scientific Presentation on Topical Issues at 2016 IABR Breath Summit in Zurich, Switzerland, September 14th-16th
BTI: 125.86 (+0.98)
Breathtec Biomedical Closes License of NA-NOSE Technology for Disease Detection
Marketwire Canada - Tue May 24, 7:01AM CDT
VANCOUVER, BC--(Marketwired - May 24, 2016) - Breathtec BioMedical, Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the "Company" or "Breathtec"
, a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of life threatening diseases is pleased to announce that further to its press release of April 13, 2016, it has now issued 1,000,000 common shares of the Company ("Shares" to Technion Research and Development Foundation Ltd., an Israeli private company and wholly-owned subsidiary of the Technion -- Israel Institute of Technology ("Technion", pursuant to a license agreement dated as of March 16, 2016 between the Company and Technion with respect to a non-exclusive license to the NA-Nose technology patents and know-how to enable commercial advancements in the field of infections detection.
BTI: 125.86 (+0.98)
Breathtec BioMedical to Present at 2016 International Association of Breath Research
Marketwire Canada - Thu Sep 08, 7:30AM CDT
Company Provides Sponsorship Support and Delivers Scientific Presentation on Topical Issues at 2016 IABR Breath Summit in Zurich, Switzerland, September 14th-16th
BTI: 125.86 (+0.98)
Breathtec Biomedical Closes License of NA-NOSE Technology for Disease Detection
Marketwire Canada - Tue May 24, 7:01AM CDT
VANCOUVER, BC--(Marketwired - May 24, 2016) - Breathtec BioMedical, Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the "Company" or "Breathtec"
, a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of life threatening diseases is pleased to announce that further to its press release of April 13, 2016, it has now issued 1,000,000 common shares of the Company ("Shares" to Technion Research and Development Foundation Ltd., an Israeli private company and wholly-owned subsidiary of the Technion -- Israel Institute of Technology ("Technion", pursuant to a license agreement dated as of March 16, 2016 between the Company and Technion with respect to a non-exclusive license to the NA-Nose technology patents and know-how to enable commercial advancements in the field of infections detection. BTI: 125.86 (+0.98)
(0)
(0)Scroll down for more posts ▼